TSC2 and neoplasm: The patient’s tumor DNA was subjected to FoundationOne® targeted next-generation sequencing [17], which revealed four oncogenic alterations: truncating mutations in TP53 and APC, a frameshift mutation in ATRX, and a deletion in TSC2, specifically, TSC2 H1746_R1751del, which has been reported both as a somatic variant in AML [18] and as a germline mutation in TSC [19].